Floatz logo

NOGITECAN

Myelodysplastic/Myeloproliferative Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

41 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
Busulphan
Jacqueline Garcia, MD
Phase 2/3BBB
CYTARABINE
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
MELPHALAN
M.D. Anderson Cancer Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

NOGITECAN is also rated in:

primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →
non-small cell lung carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →